Enoblituzumab companion diagnostic - ImaginAb
Latest Information Update: 25 Apr 2024
At a glance
- Originator ImaginAb
- Developer ImaginAb Inc
- Class Monoclonal antibody diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for Investigations in Solid tumours (Diagnosis) in USA (unspecified)
- 05 Sep 2012 Investigation in Solid tumours (diagnosis) in USA (unspecified)